Paul V. Campanelli
release a agenda call. Thank you, earnings call. thank a for X, review here's this on chance for Steve. to morning for hope brief the today's you company's we morning. and Beginning that issued slide you us that I had earlier joining Good today's
of slide full to our to X. and provide I my focus only quarter recap strategic to end offer performance. XXXX and remarks, a our and ranges. insight benefited year the EBITDA continue guidance the fourth XXXX Once of our plan financial EPS year we Endo line The additional against instead reported a adjusted brief on from fourth exceeded on is guidance. year quarter revenue Branded what and majority with In Moving full performance will range adjusted quarter comments quarters, as priorities to will Blaise growth Specialty plans of to operating guidance and solid portfolios. revenue and Injectables upper our pleased XXXX our recent most our our respective And multiyear the again, past some in his with strong and report Sterile also our plan. and fourth in Endo achieve provide results consistent full XXXX few execute quarterly company our
Moving fourth a segment will quarter. to X, snapshot our slide of the revenues you see for
of year, prior Pharmaceuticals tablets, Pharmaceutical third performance the extended-release expected, and the a of significant at XXXX, the overall generic launched very shipments (XX:XX) challenging Pharmaceuticals' Branded respectively. our OPANA divestitures ZETIA, continued products of fourth U.S. course, we for fourth U.S. Litha quarters of CT version reflects, was the tablets, business and of Somar generic of ezetimibe SEROQUEL equivalent and by generic two International competition was quetiapine the products, with in impacted XXXX, when established As faced Generic the our the XR. of comparison quarter and ER. first-to-file beginning
XXXX in the new in from XXXX and product discontinuations. is quetiapine base part ER. also annualization loss XXXX half you dosages. in well large in in ezetimibe alternative Generic resulted of events, of the as for in The in X. significant of of part events, slide marketing reflected business in the Now revenues first exclusivity resulted U.S. decline decline decline Pharmaceuticals moving and our the exclusivity from the This competitive launches to loss The competitive see as
For the approximately we line base to year, declined last guidance our XX% Generics provided compared the with business in XXXX, February.
for in XXXX Our assumptions providing the are guidance are we included today.
In partners over generic a our we work source have our and and high-quality the come of on always terms of to product trade positioning, the industry stable years. be that will know to rely
offer discontinuing longer to have tough consider with in sense terms no to we we will done profitability, decision makes make certain a to of it when it, have or as However, product drugs. we continue as whether commoditized
product of in going level lower experienced normal discontinuations will the occur our product and the expectation level we're forward some always optimistic past that meaningfully of than be months. frequency will course, in over Although XX discontinuations cautiously
maintain closely acceptable work will our profitability We levels us. at supply reliable with customers direct to for of
fourth Injectables double the digit Sterile XX% of Injectables Adrenalin, prior quarter. Sterile Powered again strong continued by versus year. the Finally, once growth growth in grew achieved
For Sterile grew provided $XX Injectables again achieved and million, respectively. guidance. and our XXXX line with Vasostrict $XXX revenue the full previously XX%, million full Adrenalin year year, revenue in sales of
as are the recent the the franchise. the of related ensuring litigation take using our or FDA's to drug agrees last of by the litigation approval public Priorities continue given We comments not expect property the believe end is Policy that the medical FDA details, company. by actions Vasostrict, its last XXXX. facilities necessary request which Endo you an know, the be FDA's appropriate FDA Vasostrict Quality outsourcing steps with along the substance taking meet health that comply amongst to statements, to a discussions will used the Plan, was by including FDA Drug And the when issued month, further FDA-approved do Act. product against recent FDA's its drug patient parties' recent whatever we Compounding drug and the defend public stay of Security announcement Endo Endo of best counsel. process Regarding a with a March with the that bulk to monitoring FDA XXXX closely can needs, initiated seek Endo to to compound and temporary be concluded patient appropriate can the protected. against a agreed to intellectual stay October by temporary the we are
to slide briefly let's turning Now U.S. discuss X, Branded Pharmaceuticals.
We be X% XIAFLEX. portfolio. across quarter, continue to pleased driven revenues solid the products primarily the our Products grew Specialty fourth growth with Specialty by Branded in
growth. pleased of Products Established XIAFLEX. the remainder flagship well OPANA revenue quarter company's our cessation by million, the of performance Branded as of of on that generic Fourth impacting expected, especially XX% As branded Products to $XX portfolio. X, ER XXXX, the by shipments strong September demand impacted Established place took product, competition adversely were the XIAFLEX as by I'm driven increased
revenue the consumer XX% as both demand effectiveness year, Peyronie's grew our increased the continued in to strong disease and of Dupuytren's our execution, For million, by $XXX activation contracture including driven XIAFLEX was in marketing revenues XXXX consistent single to were initiatives. digits This products expected year to and the with low performance grow full guidance double high XIAFLEX our that in range. was Branded Specialty
to Now slide on moving X.
take the Somar, beginning sale from due the South at and million Pharmaceuticals. Litha Let's October company's declined business, of of Mexican Fourth International to the divestiture $XX revenues of quarter business African at the of Endo's primarily prior third year, in International the XXXX. a quarter look
Our year. line Canadian Paladin business prior was broadly with in
that strategic future organic. to for be patients highly things quality be medicines and and from Endo its year We setting X. slide branded whose focus to and specialty focused was growth laid we A relied Endo which manufacturing, a in acquisitions key out vision would a a development, on clear in we we can articulated in that told outlined strategic to delivering priorities, you company, aspire primarily our control. We ago, a company that out one generic upon through Turning to transition those excellence vision, growth in need for commercialization. to
where would take to also company a for wants Importantly, this time that the get we it told multi-year represent us and would turnaround. be, to you
believe team, at so integrity year, culture a customer have undertaken success is culture with we Endo. and our priorities. relentless of And commitment a against colleagues, we've to to Over create will driven measures In series progress have execution. Since implemented created XXXX. that new executing a focused doing a continue our those past the made have values organization we leadership amongst new performance reshape we we unified a for significant collaboration a culture to in and significant operational that and so, we do flawless
We We deliver and centralized actions the organizations. served and have global with the Endo technical our improvements. supply Endo's capabilities organization R&D unified unification, future. to medical of has simplified streamlined and and centralization drive affairs, our company chain, needed one compliance, to productivity quality, have R&D now portfolio these through also
pursue simply in agnostic promising focus. core process, available and product areas to are what the determine our selection instead our most be opportunities product we and within development of We
generic the Alabama, network. integrated decisions manufacturing and over a and In past branded that approach we In of our We later XXXX us Huntsville, have two have process. our our cases the We North with of in corporate sale and closure we of tough simplified this same will pharmaceutical our believe spend restructured well some generics rationalizations R&D Charlotte, impacted productivity years facility to in better These functions functions. our in doing less resulted year the organizations. result that as the unified efficiency, our permitting these manufacturing each Carolina, XXXX, very made and greater so, as through location.
contributors. In addition, were a XX significant generic approximately we products discontinued that not total of
substantially sites, products examine more we and roster we York, our manufacture Michigan, consolidating Sterile Although be example, optimized facility simplified network well as generic at ongoing our and products we our unified both we tech-transferring for portfolio, manufacturing product Injectables and an Chestnut to site. our and as company. operationally remaining we our on our branded seeking continue to further Rochester, New Today believe sound. at product Ridge, In basis, to always our efficient have generic have
has organization these have of been goal our actions as In simplify organization our these taken to all to make it of I've to reshape actions, our for efficient outlined All success. X,XXX been XXXX, has possible. employees Endo. employees worldwide. been decisions. at Today, and more has easy effective difficult In approximately had not as X,XXX than Endo there and Achieving this are necessitated undertaking
and critically future However, businesses undertaking capabilities and and at our for capabilities portfolio to and savings for pain we terminated assets used assets future and that products force, all non-core actions and remains areas of to a by ceased product these importantly, assets, product our divested our portfolio ER products opioid that identified company's physicians, us core those an Endo. Building Generics to core sales and including not We this identified key portfolios. namely products. have began programs. Litha withdrew being OPANA our other and of We from overall build resources were We from We pipeline expansion. Branded redirected important pain divested assessment margin those that growth, to development and drive Specialty promoting of priority the the We as market, the Somar. us them. are a and its hard-to-produce our strategy mission generated behind areas of disbanded
Speaking injection, disadvantage. Nevertheless, share permit is of of and you risk visibility ephedrine launched as pipeline including first-to-market On XXXX in into our the at can. products, vigabatrin, provide our product, injection, placing me it running oral XX to neostigmine to I always competitive difficult pipeline, ourselves what solution. without slide know a X, Par Generics for a
about We XXXX. in dozen also a regulatory filings submitted
many that now mentioned quality of launch today has over and have which we've again a products, with patient recognize an significant to into I powder to ER past products impacting less number share capsules. the as submit product existing the filings – company. assistant the to XXXX. to generic record it place products sodium as a XX market pace ANDAs of the more continuing industry been that significant memantine categories, we combined pharmacies we we've is customers, I'm August. first-to-market Vigabatrin phenylbutyrate ANDAs the been Quite launch competition. pleased vigabatrin available a that did launched able the trade challenges It's ever. last retail has took partners than date, matter the neighborhood for those providers generics frankly, patient the relevant, primarily files company program. as complicated two consolidation of of expect XXXX, FDA For at ANDAs years. The have three oral very achieve in at introduction and for of certified retail intense solution and all healthcare product resource. sector least and through in together heighten To We U.S. already approving a few our presence. generics the a in represented to requires of for extensive and essentially specialty only The a REMS new become dedicated
maintain years the teams. pending U.S. and a that Of me product experience vigabatrin successful introductions, pharmacy launch such most represent of reinforced Our of value been sales sales peptides [Injectables] litigation first-to-market collaboration Specialty of pursuant of products or settled for and these cases, patent branded XXXX products The we ANDA help several Among corresponding launch This of entry first-to-file been have the ANDAs annual XXXX. hard-to-produce phenylbutyrate challenging the made are with take and which further a market our than BUPHENYL, settled also GATTEX, with focusing approximately successful first-to-market pending U.S. terms. The represented specialty first-to-file and introductions our the expertise vigabatrin the more that opportunities products development To in view of or distribution. represent These new combined XXX pharmacies. XX Branded network. continuing number polypeptides, sodium with specialty business pharmacy both first-to-market to on vigabatrin to in more of confidential experience flow billion several version pending very the submissions ANDAs hybrid of filed has Sterile than require as distribution available launches a Furthermore, our of ANDAs required has in tablets, FDA. approximately In $XX Generics, is marketing specialty successfully dates ANDAs XX include teduglutide, are a products surrounding shared develop. the generic litigation company model. Endo and marketing product strong reinforced we my of The that equivalent opportunities. determined. through to that and to are generic our will
expected CIPRODEX, KUVAN assets generic been can portfolio MITIGARE. contributing AFINITOR, investing Some and products versions AMITIZA, examples these date of include beyond. The be certain of have begin in around and XXXX we of DEXILANT, which to
cellulite and be be of turning we Now of earlier The treatment third-party dimples be clostridium and of this the experts. by of enrolled occurring release is Each composite XXX of a and big randomized, early appearance demonstrating validated composite visit primary using are visit the severity cellulite to expected in studies news trials in cellulite cellulite. The At placebo a of left end with evaluate for receive reducing the psychometric reported histolyticum, or cellulite. the photonumeric moderate or two to XX visits the clinical CCH, will photonumeric of CCH developed The In safety outset and initiation clinician by and placebo patients. two Endo up with into XX, on States both the administered analysis our slide approximately women three efficacy treatment, multicenter, to These studies assessed each improvement, X point Specialty. days least patient a level XX controlled scale in will each XXX right treatment will two the will is United of treatment CCH severity. Branded February course both and of by areas, treatment cellulite and severity be injections of each women clinician scales the pivotal trial. enroll severe independently at Phase The responder will with of double collagenase conclusion XX each total buttocks. during conducted blind, the apart. month across each two patient first subject older cellulite. to will years or
several secondary key In endpoints. addition, are there
XXXX this is line you. Endo forward those and and sharing We success. look from for prospects the first entire about results The study excited in quarter with team to very results expect of the top our opportunity
cellulite. is located of of to physicians mostly is buttocks, high disrupts, this When volume fat Despite amongst dimpling, there indicates the fibrous action cause. the dimpling, fibrous literature CCH the slide around of approved caused core date, there believe cellulite, the the the with new and debate of incident septae to most to of Cellulite the To etiology or understanding. septae tethering of to its The and about septae. FDA resulting which mechanism all product been XX. fibrous the has cell Moving on to the to return the as is The primary septae, cause and cause by address the women lower and be consensus abnormality abdomen, XX% affect as recent will to for the enzymatically dimple injected, condition, is thighs, lyses, much this aesthetic arms, races. no root contour secondary cellulite. the treat of CCH of a We contour. in releasing XX% skin being the the post-pubertal skin permitting continues still normal in
believe aesthetics X% non-surgical sculpting growing As when both a more an market Society at and injectable growing non-invasive cellulite. into such market treatment are number us be The $XX Surgery is market billion brings injectable is billion one for the U.S. for entering Dermatologic an XXXX with for American that a include annually. FDA survey, of With to a approved need That a especially is effective than is to the we for cellulite, surgical According procedure is aesthetics there market and consumers consumer to $X.X market slide considering. you no procedures. body result, the and is XX. The treatment time opportunity. U.S. unmet safe total significant potentially exciting it
were regulatory dermatologists and plastic for of see also from product the surgeons shown the in either very true were healthcare this XX% hand Over is market. excited It patients survey both upon treatment high, to potentially a CCH pharmaceutical for slide the their that and a results potential surgeons You both to profile. excited a the side could new unusual so offer cellulite represent to suggesting approval. score professionals extremely plastic dermatologists or innovation on could of see which right CCH product
there numerous CCH. have pleased marketing Endo countries potential addition, for since rights are In represent international is for the product, to that attractive markets
and all As XXXX. treatment CCH designed plan X observe development the septae look in with And of indication thigh Phase collaborative buttocks have way seeking market and of approach forward to buttocks fibrous cellulite. and to a in significant in we've the to will of FDA, submitting quickest view generation thighs. robust program the the on to to a the we effect We outlined the address data and a treatment and result we We for process data an treatment be with be this unmet need. a simplest
key preparing we attract able launch planning. preliminary am our aesthetic say been are commercial experience to talent we additions are top We have substantial build aesthetics best-in-class already companies. at our to continue These for shaping and to pleased as aesthetics to success contributing team. I with prior
as this direct including our efforts Although network believe excited both do sales of our disease talented will inline I without success activation to in we we interpret operational via flawless relationships. and effective could specialty XIAFLEX continue Dupuytren's XX% off as year indications, to there mentioned In management our was attention well marketing pharmacy detail not is increase eye Furthermore, the to digital achieved to as which taking achieved we revenue have we about consumer The the treatment invest consumer initiatives, recorded of XXXX, been please for awareness inline are result both professionals growth we that current outreach. our further our earlier. for opportunity are Peyronie's full-year diagnosis continue to of XIAFLEX indications. and rates for indications not cellulite the of disease or the suggest the behind to state and and contracture great execution opportunity, we these that
provide Coleman let the me and quarter Blaise? Now detailed guidance. XXXX turn to to financial financial company's call discuss our to the Blaise over fourth performance further
